Oral Hypoglycemic Agents Global Market Report 2025

Description

Oral hypoglycemic agents (OHAs) are medications taken orally to help reduce blood glucose (sugar) levels in individuals with type 2 diabetes mellitus. These medications work through different mechanisms, including increasing insulin secretion, enhancing insulin sensitivity, decreasing glucose absorption from the gut, or reducing glucose production by the liver. OHAs are typically prescribed when lifestyle changes, such as diet and exercise, are not enough to control blood sugar levels.

The primary types of oral hypoglycemic agents include sulfonylureas, metformin, thiazolidinediones, alpha-glucosidase inhibitors, and immunotherapy. Sulfonylureas are a class of oral hypoglycemic agents that stimulate the pancreas to release more insulin by targeting beta cells, which helps lower blood glucose levels in individuals with type 2 diabetes. These drugs are available in various forms, such as oral tablets, oral liquids, extended-release formulations, and combination therapy formulations. The patient groups include individuals with type 2 diabetes mellitus, pre-diabetic patients, obese or overweight individuals, and those with multiple comorbidities. They are distributed through various channels like hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes or long-term care facilities. The main end users are hospitals and clinics.

The oral hypoglycemic agents market research report is one of a series of new reports from The Business Research Company that provides oral hypoglycemic agents market statistics, including the oral hypoglycemic agents industry global market size, regional shares, competitors with the oral hypoglycemic agents market share, detailed oral hypoglycemic agents market segments, market trends, and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. This oral hypoglycemic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral hypoglycemic agents market size has grown strongly in recent years. It will grow from $57.04 billion in 2024 to $60.15 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to factors such as the increasing prevalence of type 2 diabetes, a rising geriatric population, greater awareness of diabetes management, expanded healthcare access in emerging markets, and a preference for oral therapies over injectable ones.

The oral hypoglycemic agents market size is expected to see strong growth in the next few years. It will grow to $73.69 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. In the forecast period, growth is expected to be driven by a rising demand for combination therapies, supportive government healthcare policies, increased adoption of telemedicine for diabetes care, greater investment in research and development for diabetes treatments, and a stronger focus on personalized treatment approaches. Key trends in this period include the development of novel oral antidiabetic drugs, the creation of fixed-dose combinations, advancements in drug formulation technologies, efforts to reduce drug side effects, and the integration of digital health tools for glucose monitoring.

The increasing prevalence of type 2 diabetes is expected to drive the growth of the oral hypoglycemic agents market. Type 2 diabetes is a chronic metabolic disorder where the body becomes ineffective in using insulin, resulting in high blood glucose levels. The rise in type 2 diabetes is largely due to more sedentary lifestyles, which reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents are used to manage type 2 diabetes by lowering blood glucose through mechanisms such as improving insulin sensitivity, stimulating insulin production, or reducing glucose absorption. According to the International Diabetes Federation (IDF), nearly 589 million adults aged 20-79 are living with diabetes worldwide as of April 2025, and this number is projected to rise to 853 million by 2050. This increasing incidence of type 2 diabetes is expected to drive market growth for oral hypoglycemic agents.

Leading companies in the oral hypoglycemic agents market are concentrating on developing advanced therapeutic options, including dipeptidyl peptidase-4 (DPP-4) inhibitors, to enhance blood sugar control for type 2 diabetes patients. DPP-4 inhibitors are medications that increase incretin hormone levels, stimulating insulin production to reduce blood sugar levels. For example, in June 2022, Gan & Lee Pharmaceuticals Co. Ltd., a China-based pharmaceutical company, received approval for Sitagliptin Phosphate tablets, an oral hypoglycemic medication designed to manage type 2 diabetes effectively. This product works by inhibiting the DPP-4 enzyme, helping regulate blood sugar levels, and marks Gan & Lee Pharmaceuticals' entry into the generic drug market, offering a more affordable option for managing type 2 diabetes.

In July 2024, F. Hoffmann-La Roche Ltd., a Swiss pharmaceutical company, acquired Carmot Therapeutics Inc. for \$2.7 billion. This acquisition allows Roche to strengthen its position in the obesity and diabetes treatment market by expanding its portfolio of incretin-based therapies. Carmot Therapeutics Inc., based in the US, specializes in developing incretin-based treatments for obesity, diabetes, and related metabolic conditions.

Major players in the oral hypoglycemic agents market are Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.

North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral hypoglycemic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral hypoglycemic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Hypoglycemic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral hypoglycemic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral hypoglycemic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral hypoglycemic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Sulfonylureas; Metformin; Thiazolidinediones; Alpha-Glucosidase Inhibitors; Immunotherapy
2) By Administration Route: Oral Tablets; Oral Liquids; Extended-Release Formulations; Combination Therapy Formulations
3) By Patient Type: Type 2 Diabetes Mellitus Patients; Pre-diabetic Patients; Obese Or Overweight Patients; Patients with Multiple Comorbidities
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Nursing Homes and Long-Term Care Facilities
5) By End users: Hospitals; Clinics
Subsegments:
1) By Sulfonylureas: Glipizide; Glyburide; Glimepiride; Chlorpropamide; Tolbutamide
2) By Metformin: Immediate-Release Metformin; Extended-Release Metformin (XR); Combination Metformin
3) By Thiazolidinediones (TZDs): Pioglitazone; Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol; Voglibose
5) By Immunotherapy: Teplizumab; Alum-Formulated GAD (GAD-Alum); Diamyd; Anti-CD3 Monoclonal Antibodies
Companies Mentioned: Pfizer Inc.; Janssen Global Services LLC; Merck Sharp & Dohme Corp.; Bayer AG; Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35538

1. Executive Summary

2. Oral Hypoglycemic Agents Market Characteristics

3. Oral Hypoglycemic Agents Market Trends And Strategies

4. Oral Hypoglycemic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oral Hypoglycemic Agents Growth Analysis And Strategic Analysis Framework

5.1. Global Oral Hypoglycemic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oral Hypoglycemic Agents Market Growth Rate Analysis
5.4. Global Oral Hypoglycemic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oral Hypoglycemic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oral Hypoglycemic Agents Total Addressable Market (TAM)

6. Oral Hypoglycemic Agents Market Segmentation

6.1. Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Immunotherapy
6.2. Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablets
Oral Liquids
Extended-Release Formulations
Combination Therapy Formulations
6.3. Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 2 Diabetes Mellitus Patients
Pre-Diabetic Patients
Obese Or Overweight Patients
Patients With Multiple Comorbidities
6.4. Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Nursing Homes and Long-Term Care Facilities
6.5. Global Oral Hypoglycemic Agents Market, Segmentation By End users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
6.6. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glipizide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
6.7. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate-Release Metformin
Extended-Release Metformin (XR)
Combination Metformin
6.8. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pioglitazone
Rosiglitazone
6.9. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acarbose
Miglitol
Voglibose
6.10. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Teplizumab
Alum-Formulated GAD (GAD-Alum)
Diamyd
Anti-CD3 Monoclonal Antibodies

7. Oral Hypoglycemic Agents Market Regional And Country Analysis

7.1. Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Hypoglycemic Agents Market

8.1. Asia-Pacific Oral Hypoglycemic Agents Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Hypoglycemic Agents Market

9.1. China Oral Hypoglycemic Agents Market Overview
9.2. China Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Hypoglycemic Agents Market

10.1. India Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Hypoglycemic Agents Market

11.1. Japan Oral Hypoglycemic Agents Market Overview
11.2. Japan Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Hypoglycemic Agents Market

12.1. Australia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Hypoglycemic Agents Market

13.1. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Hypoglycemic Agents Market

14.1. South Korea Oral Hypoglycemic Agents Market Overview
14.2. South Korea Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Hypoglycemic Agents Market

15.1. Western Europe Oral Hypoglycemic Agents Market Overview
15.2. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Hypoglycemic Agents Market

16.1. UK Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Hypoglycemic Agents Market

17.1. Germany Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Hypoglycemic Agents Market

18.1. France Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Hypoglycemic Agents Market

19.1. Italy Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Hypoglycemic Agents Market

20.1. Spain Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Hypoglycemic Agents Market

21.1. Eastern Europe Oral Hypoglycemic Agents Market Overview
21.2. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Hypoglycemic Agents Market

22.1. Russia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Hypoglycemic Agents Market

23.1. North America Oral Hypoglycemic Agents Market Overview
23.2. North America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Hypoglycemic Agents Market

24.1. USA Oral Hypoglycemic Agents Market Overview
24.2. USA Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Hypoglycemic Agents Market

25.1. Canada Oral Hypoglycemic Agents Market Overview
25.2. Canada Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Hypoglycemic Agents Market

26.1. South America Oral Hypoglycemic Agents Market Overview
26.2. South America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Hypoglycemic Agents Market

27.1. Brazil Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Hypoglycemic Agents Market

28.1. Middle East Oral Hypoglycemic Agents Market Overview
28.2. Middle East Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Hypoglycemic Agents Market

29.1. Africa Oral Hypoglycemic Agents Market Overview
29.2. Africa Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Hypoglycemic Agents Market Competitive Landscape And Company Profiles

30.1. Oral Hypoglycemic Agents Market Competitive Landscape
30.2. Oral Hypoglycemic Agents Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Janssen Global Services LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck Sharp & Dohme Corp. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Oral Hypoglycemic Agents Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca plc
31.3. Novartis AG
31.4. GSK plc
31.5. Takeda Pharmaceuticals Limited
31.6. Eli Lilly and Company
31.7. Boehringer Ingelheim Ltd.
31.8. Novo Nordisk A/S
31.9. Astellas Pharma Inc.
31.10. Laboratoires Servier
31.11. Huadong Medicine Co. Ltd.
31.12. Tonghua Dongbao Pharmaceutical Co. Ltd.
31.13. Gan & Lee Pharmaceuticals Co. Ltd.
31.14. Biocon Limited
31.15. Wanbang Biopharmaceuticals Co. Ltd.

32. Global Oral Hypoglycemic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Hypoglycemic Agents Market

34. Recent Developments In The Oral Hypoglycemic Agents Market

35. Oral Hypoglycemic Agents Market High Potential Countries, Segments and Strategies

35.1 Oral Hypoglycemic Agents Market In 2029 - Countries Offering Most New Opportunities
35.2 Oral Hypoglycemic Agents Market In 2029 - Segments Offering Most New Opportunities
35.3 Oral Hypoglycemic Agents Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer